New exploratory findings demonstrate that in responders with IGFBP7 biomarker decline, CNM-Au8 30mg was strongly associated ...

Health Canada has cleared the way for ALS patients in that nation to join the ongoing ALSTARS U.S. trial testing therapy ...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel ...

QRL-101, an oral small molecule being developed by QurAlis, was safe and reduced nerve-cell overactivity in ALS patients in ...

A new international study has demonstrated that Alzheimer's disease biomarkers can be accurately detected using simple finger ...

According to MarketsandMarkets, the Genomic Biomarkers Market is projected to grow from about USD 29.00 billion in 2025 to USD 50.31 billion ...

A groundbreaking international study has demonstrated that Alzheimer's disease biomarkers can be accurately detected using ...

Ractigen Therapeutics is pleased to announce that the first patient has been dosed in the Phase II clinical trial of RAG-17, an innovative siRNA therapy targeting SOD1-mutated amyotrophic lateral ...

928,333 shares of common stock and accompanying warrants at an offering price of $6.50 per unit for each investor, totaling $6.03 million of gross proceeds, which is expected to fund Clene into the ...

First-in-class condensate-modulating small molecule Development Candidate targeting pathogenic TDP-43 condensates.Restores global TDP-43 splicing ...